Jump to navigation Jump to search
|Target||staphylococcal lipoteichoic acid|
|Chemical and physical data|
|Molar mass||072.36 g·mol−1 146|
|(what is this?)|
Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010[update], it is undergoing Phase II/III clinical trials.
- Weisman, LE; Thackray, HM; Garcia-Prats, JA; Nesin, M; Schneider, JH; Fretz, J; Kokai-Kun, JF; Mond, JJ; Kramer, WG (2009). "Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates". Antimicrobial Agents and Chemotherapy. 53 (7): 2879–86. doi:10.1128/AAC.01565-08. PMC 2704668. PMID 19380597.
- Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|